{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T02:49:43Z","timestamp":1779936583875,"version":"3.53.1"},"reference-count":55,"publisher":"American Association for Cancer Research (AACR)","issue":"6","license":[{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"HHS | NIH | NCI | National Cancer Institute","award":["P50CA127001"],"award-info":[{"award-number":["P50CA127001"]}]},{"name":"HHS | NIH | NCI | National Cancer Institute","award":["R01CA256006"],"award-info":[{"award-number":["R01CA256006"]}]},{"name":"The University Cancer Foundation via the Institution Research Grant program at The University of Texas MD Anderson Cancer Center"},{"name":"the John and Rebekah Harper Fellowship"},{"name":"HHS | NIH | NCI | National Cancer Institute","award":["P30CA01667"],"award-info":[{"award-number":["P30CA01667"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,27]]},"abstract":"<jats:p>Cancer cell heterogeneity and immunosuppressive tumor microenvironment (TME) pose a challenge in treating solid tumors with adoptive cell therapies targeting limited tumor-associated antigens (TAA), such as chimeric antigen receptor T-cell therapy. We hypothesize that oncolytic adenovirus Delta-24-RGDOX activates the TME and promote antigen spread to potentiate the abscopal effect of adoptive TAA-targeting T cells in localized intratumoral treatment. Herein, we used C57BL\/6 mouse models with disseminated tumors derived from B16 melanoma cell lines to assess therapeutic effects and antitumor immunity. gp100-specific pmel-1 or ovalbumin (OVA)-specific OT-I T cells were injected into the first subcutaneous tumor, followed by three injections of Delta-24-RGDOX. We found TAA-targeting T cells injected into one subcutaneous tumor showed tumor tropism. Delta-24-RGDOX sustained the systemic tumor regression mediated by the T cells, leading to improved survival rate. Further analysis revealed that, in mice with disseminated B16-OVA tumors, Delta-24-RGDOX increased CD8+ leukocyte density within treated and untreated tumors. Importantly, Delta-24-RGDOX significantly reduced the immunosuppression of endogenous OVA-specific CTLs while increasing that of CD8+ leukocytes and, to a lesser extent, adoptive pmel-1 T cells. Consequently, Delta-24-RGDOX drastically increased the density of the OVA-specific CTLs in both tumors, and the combination synergistically enhanced the effect. Consistently, the splenocytes from the combination group showed a significantly stronger response against other TAAs (OVA and TRP2) than gp100, resulted in higher activity against tumor cells. Therefore, our data demonstrate that, as an adjuvant therapy followed TAA-targeting T cells in localized treatment, Delta-24-RGDOX activates TME and promotes antigen spread, leading to efficacious systemic antitumor immunity to overcome tumor relapse.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Adjuvant therapy with oncolytic viruses promotes antigen spread to potentiate localized intratumoral adoptive T-cell therapy with limited TAA targets, leading to sustainable systemic antitumor immunity to overcome tumor relapse.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-23-0054","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T19:28:48Z","timestamp":1680290928000},"page":"1118-1131","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity"],"prefix":"10.1158","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4668-5319","authenticated-orcid":true,"given":"Hong","family":"Jiang","sequence":"first","affiliation":[{"name":"1Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0135-0817","authenticated-orcid":true,"given":"Dong Ho","family":"Shin","sequence":"additional","affiliation":[{"name":"1Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2256-9192","authenticated-orcid":true,"given":"Yanhua","family":"Yi","sequence":"additional","affiliation":[{"name":"1Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4648-0287","authenticated-orcid":true,"given":"Xuejun","family":"Fan","sequence":"additional","affiliation":[{"name":"1Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1057-1285","authenticated-orcid":true,"given":"Joy","family":"Gumin","sequence":"additional","affiliation":[{"name":"2Department of Neuro-Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7479-4315","authenticated-orcid":true,"given":"Jiasen","family":"He","sequence":"additional","affiliation":[{"name":"3Pediatric division, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9704-7459","authenticated-orcid":true,"given":"Andrew G.","family":"Gillard","sequence":"additional","affiliation":[{"name":"1Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3747-873X","authenticated-orcid":true,"given":"Frederick F.","family":"Lang","sequence":"additional","affiliation":[{"name":"2Department of Neuro-Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1259-2133","authenticated-orcid":true,"given":"Candelaria","family":"Gomez-Manzano","sequence":"additional","affiliation":[{"name":"1Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6941-2335","authenticated-orcid":true,"given":"Juan","family":"Fueyo","sequence":"additional","affiliation":[{"name":"1Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,6,27]]},"reference":[{"key":"2023062714084671200_bib1","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1126\/science.1203543","article-title":"A perspective on cancer cell metastasis","volume":"331","author":"Chaffer","year":"2011","journal-title":"Science"},{"key":"2023062714084671200_bib2","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","article-title":"CAR T cell therapy for solid tumors: bright future or dark reality?","volume":"28","author":"Wagner","year":"2020","journal-title":"Mol Ther"},{"key":"2023062714084671200_bib3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"2023062714084671200_bib4","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3389\/fimmu.2017.01617","article-title":"Recent successes and future directions in immunotherapy of cutaneous melanoma","volume":"8","author":"Sadozai","year":"2017","journal-title":"Front Immunol"},{"key":"2023062714084671200_bib5","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"key":"2023062714084671200_bib6","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med"},{"key":"2023062714084671200_bib7","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"2023062714084671200_bib8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.coviro.2015.03.009","article-title":"Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints","volume":"13","author":"Jiang","year":"2015","journal-title":"Curr Opin Virol"},{"key":"2023062714084671200_bib9","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"2023062714084671200_bib10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"Fueyo","year":"2000","journal-title":"Oncogene"},{"key":"2023062714084671200_bib11","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jnci\/95.9.652","article-title":"Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway","volume":"95","author":"Fueyo","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2023062714084671200_bib12","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/jnci\/djm102","article-title":"Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death","volume":"99","author":"Jiang","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2023062714084671200_bib13","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J Clin Oncol"},{"key":"2023062714084671200_bib14","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/0008-5472.CAN-17-0468","article-title":"Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination","volume":"77","author":"Jiang","year":"2017","journal-title":"Cancer Res"},{"key":"2023062714084671200_bib15","doi-asserted-by":"crossref","first-page":"6801","DOI":"10.1158\/1078-0432.CCR-19-0405","article-title":"Localized treatment with oncolytic adenovirus delta-24-RGDOX induces systemic immunity against disseminated subcutaneous and intracranial melanomas","volume":"25","author":"Jiang","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2023062714084671200_bib16","doi-asserted-by":"crossref","first-page":"e001486","DOI":"10.1136\/jitc-2020-001486","article-title":"Clinical landscape of oncolytic virus research in 2020","volume":"8","author":"Macedo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2023062714084671200_bib17","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.3389\/fimmu.2018.02460","article-title":"CAR-T cells and oncolytic viruses: joining forces to overcome the solid tumor challenge","volume":"9","author":"Guedan","year":"2018","journal-title":"Front Immunol"},{"key":"2023062714084671200_bib18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1089\/hum.2020.278","article-title":"Combining oncolytic viruses with chimeric antigen receptor T cell therapy","volume":"32","author":"McGrath","year":"2021","journal-title":"Hum Gene Ther"},{"key":"2023062714084671200_bib19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ymthe.2020.10.023","article-title":"Clinical CAR-T cell and oncolytic virotherapy for cancer treatment","volume":"29","author":"Watanabe","year":"2021","journal-title":"Mol Ther"},{"key":"2023062714084671200_bib20","doi-asserted-by":"crossref","first-page":"e97407","DOI":"10.1371\/journal.pone.0097407","article-title":"Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model","volume":"9","author":"Jiang","year":"2014","journal-title":"PLoS One"},{"key":"2023062714084671200_bib21","doi-asserted-by":"crossref","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci Transl Med"},{"key":"2023062714084671200_bib22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jim.2015.01.004","article-title":"A reproducible method for the expansion of mouse CD8+ T lymphocytes","volume":"417","author":"Lewis","year":"2015","journal-title":"J Immunol Methods"},{"key":"2023062714084671200_bib23","doi-asserted-by":"crossref","first-page":"e1000412","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"8","author":"Kilkenny","year":"2010","journal-title":"PLoS Biol"},{"key":"2023062714084671200_bib24","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","article-title":"Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"2023062714084671200_bib25","doi-asserted-by":"crossref","first-page":"12397","DOI":"10.1128\/JVI.01420-14","article-title":"High frequencies of polyfunctional CD8+ NK cells in chronic HIV-1 infection are associated with slower disease progression","volume":"88","author":"Ahmad","year":"2014","journal-title":"J Virol"},{"key":"2023062714084671200_bib26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.0105-2896.2009.00870.x","article-title":"The CD8+ dendritic cell subset","volume":"234","author":"Shortman","year":"2010","journal-title":"Immunol Rev"},{"key":"2023062714084671200_bib27","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3389\/fimmu.2018.00678","article-title":"The CD8 T cell response to respiratory virus infections","volume":"9","author":"Schmidt","year":"2018","journal-title":"Front Immunol"},{"key":"2023062714084671200_bib28","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.4049\/jimmunol.159.4.1686","article-title":"Mechanisms of L-selectin regulation by activated T cells","volume":"159","author":"Chao","year":"1997","journal-title":"J Immunol"},{"key":"2023062714084671200_bib29","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1084\/jem.20030485","article-title":"L-selectin shedding does not regulate constitutive T cell trafficking but controls the migration pathways of antigen-activated T lymphocytes","volume":"198","author":"Galkina","year":"2003","journal-title":"J Exp Med"},{"key":"2023062714084671200_bib30","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1126\/science.2551036","article-title":"Neutrophil Mac-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors","volume":"245","author":"Kishimoto","year":"1989","journal-title":"Science"},{"key":"2023062714084671200_bib31","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1084\/jem.185.3.453","article-title":"Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma","volume":"185","author":"Bloom","year":"1997","journal-title":"J Exp Med"},{"key":"2023062714084671200_bib32","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2023062714084671200_bib33","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"2023062714084671200_bib34","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.3389\/fimmu.2018.02103","article-title":"Oncolytic viruses partner with T-cell therapy for solid tumor treatment","volume":"9","author":"Shaw","year":"2018","journal-title":"Front Immunol"},{"key":"2023062714084671200_bib35","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3389\/fimmu.2017.01850","article-title":"Chimeric antigen receptors T cell therapy in solid tumor: challenges and clinical applications","volume":"8","author":"Mirzaei","year":"2017","journal-title":"Front Immunol"},{"key":"2023062714084671200_bib36","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40425-018-0340-z","article-title":"Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells","volume":"6","author":"Nellan","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2023062714084671200_bib37","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.canlet.2017.02.015","article-title":"Intracavitary \u0218T4 immunotherapy\u0219 of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells","volume":"393","author":"Klampatsa","year":"2017","journal-title":"Cancer Lett"},{"key":"2023062714084671200_bib38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-17-2041","article-title":"Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2(+) breast cancer metastasis to the brain","volume":"24","author":"Priceman","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2023062714084671200_bib39","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med"},{"key":"2023062714084671200_bib40","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/cgt.2016.14","article-title":"Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery","volume":"23","author":"Katz","year":"2016","journal-title":"Cancer Gene Ther"},{"key":"2023062714084671200_bib41","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1158\/0008-5472.CAN-06-3974","article-title":"Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus","volume":"67","author":"Diaz","year":"2007","journal-title":"Cancer Res"},{"key":"2023062714084671200_bib42","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1002\/cncr.30491","article-title":"Adoptive T cell therapy: an overview of obstacles and opportunities","volume":"123","author":"Baruch","year":"2017","journal-title":"Cancer"},{"key":"2023062714084671200_bib43","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1084\/jem.182.2.519","article-title":"Structural requirements regulate endoproteolytic release of the L-selectin (CD62L) adhesion receptor from the cell surface of leukocytes","volume":"182","author":"Chen","year":"1995","journal-title":"J Exp Med"},{"key":"2023062714084671200_bib44","doi-asserted-by":"crossref","first-page":"e22560","DOI":"10.1371\/journal.pone.0022560","article-title":"The shedding of CD62L (L-selectin) regulates the acquisition of lytic activity in human tumor reactive T lymphocytes","volume":"6","author":"Yang","year":"2011","journal-title":"PLoS One"},{"key":"2023062714084671200_bib45","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2023062714084671200_bib46","doi-asserted-by":"crossref","first-page":"e1364828","DOI":"10.1080\/2162402X.2017.1364828","article-title":"PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy?","volume":"7","author":"Simon","year":"2018","journal-title":"Oncoimmunology"},{"key":"2023062714084671200_bib47","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2023062714084671200_bib48","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"2023062714084671200_bib49","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.4049\/jimmunol.0900080","article-title":"PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo","volume":"182","author":"Chikuma","year":"2009","journal-title":"J Immunol"},{"key":"2023062714084671200_bib50","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.immuni.2011.06.015","article-title":"Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells","volume":"35","author":"Youngblood","year":"2011","journal-title":"Immunity"},{"key":"2023062714084671200_bib51","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"2023062714084671200_bib52","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.omto.2020.03.018","article-title":"Viral delivery of CAR targets to solid tumors enables effective cell therapy","volume":"17","author":"Aalipour","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"2023062714084671200_bib53","doi-asserted-by":"crossref","first-page":"eaaz1863","DOI":"10.1126\/scitranslmed.aaz1863","article-title":"Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors","volume":"12","author":"Park","year":"2020","journal-title":"Sci Transl Med"},{"key":"2023062714084671200_bib54","doi-asserted-by":"crossref","first-page":"eabn2231","DOI":"10.1126\/scitranslmed.abn2231","article-title":"Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice","volume":"14","author":"Evgin","year":"2022","journal-title":"Sci Transl Med"},{"key":"2023062714084671200_bib55","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1089\/hum.2012.030","article-title":"Adsoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escape","volume":"23","author":"Kaluza","year":"2012","journal-title":"Hum Gene Ther"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-23-0054\/3317749\/crc-23-0054.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/6\/1118\/3343477\/crc-23-0054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/6\/1118\/3343477\/crc-23-0054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T11:06:56Z","timestamp":1687864016000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/3\/6\/1118\/727509\/Adjuvant-Therapy-with-Oncolytic-Adenovirus-Delta"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,27]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,27]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-23-0054","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.23587245","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587233","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587218.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587221","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587230.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587215.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587248.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587251.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587242","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587230","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587218","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587251","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587239","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587227","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587215","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587242.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587236","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587224","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587245.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587239.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587236.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587248","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587233.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587227.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587221.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587224.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.23587227","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587239","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22435849","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587215","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22435861.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587251","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22435849.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22435861","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587227.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587224.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587221.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22435858","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6515128.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587236","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22435864.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587248","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22435867.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587224","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22435867","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22435855","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587215.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6515128.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587221","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587233","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587245","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587230.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587218.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6515128","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22435858.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22435855.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22435852.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587242.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587218","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22435864","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22435852","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587251.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587239.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587233.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587236.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587230","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587242","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587245.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23587248.v1","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,27]]}}}